Raloxifene vs placebo
The review found no eligible studies for this question.
- Selective oestrogen receptor modulators (SERMs) for endometriosis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
The review found no eligible studies for this question.
It is very uncertain whether raloxifene changes adverse events ‐ pelvic pain compared with placebo (very low certainty).
It is very uncertain whether raloxifene changes adverse events ‐ ovarian cyst compared with placebo (very low certainty).
It is very uncertain whether raloxifene changes adverse events ‐ headache compared with placebo (very low certainty).
It is very uncertain whether raloxifene changes adverse events ‐ migraine compared with placebo (very low certainty).
It is very uncertain whether raloxifene changes adverse events ‐ depression compared with placebo (very low certainty).
It is very uncertain whether raloxifene changes biopsy‐proven recurrence of endometriosis compared with placebo (very low certainty).